Highlights & Basics
- Healthcare professionals play a central role in motivating and assisting patients to quit smoking.
- Smoking cessation benefits all people who smoke regardless of age, comorbidities, or current health problems.
- Ask: systems should be established in each clinic that identify the smoking status of each patient and that communicate this status to physicians.
- Advise: a personalized, open, and reflective patient-centered discussion should be provided on how smoking cessation can help patients achieve their goals.
- Assess: it should be determined whether patients are ready to consider attempting to quit and, if ready, how confident they are about success.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Images
Significant survival benefit of smoking cessation
Prompt for smoking, with additional questions automatically opened depending on each answer
Prompt for e-cigarette use, typically completed by the intake staff and discussed by the healthcare provider
Example script and color-coded sticker system for identifying smoking status with vital signs
Example method to indicate smoking status on the vital signs record
Questionnaire to assess and improve motivation and self-confidence for quitting effort
Algorithm for tailoring pharmacotherapy for smoking cessation
Citations
United States Public Health Service Office of the Surgeon General; National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. Smoking cessation: a report of the surgeon general. 2020 [internet publication].[Abstract][Full Text]
Fiore MC, Jaén CR, Baker TB, et al; US Department of Health and Human Services. Treating tobacco use and dependence: 2008 update. May 2008 [internet publication].[Full Text]
US Preventive Services Task Force; Krist AH, Davidson KW, Mangione CM, et al. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. JAMA. 2021 Jan 19;325(3):265-79.[Abstract][Full Text]
Barua RS, Rigotti NA, Benowitz NL, et al. 2018 ACC expert consensus decision pathway on tobacco cessation treatment: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2018 Dec 5;72(25):3332-65.[Abstract][Full Text]
Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018 May 31;(5):CD000146.[Abstract][Full Text]
Bader P, McDonald P, Selby P. An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts. Tob Control. 2009 Feb;18(1):34-42. [Abstract][Full Text]
1. United States Public Health Service Office of the Surgeon General; National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. Smoking cessation: a report of the surgeon general. 2020 [internet publication].[Abstract][Full Text]
2. Fiore MC, Jaén CR, Baker TB, et al; US Department of Health and Human Services. Treating tobacco use and dependence: 2008 update. May 2008 [internet publication].[Full Text]
3. Maciosek MV, LaFrance AB, Dehmer SP, et al. Updated priorities among effective clinical preventive services. Ann Fam Med. 2017 Jan;15(1):14-22.[Abstract][Full Text]
4. Cornelius ME, Loretan CG, Wang TW, et al. Tobacco product use among adults - United States, 2020. MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):397-405.[Abstract][Full Text]
5. GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet. 2021 Jun 19;397(10292):2337-60.[Abstract][Full Text]
6. Park-Lee E, Ren C, Cooper M, et al. Tobacco product use among middle and high school students - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Nov 11;71(45):1429-35.[Abstract][Full Text]
7. World Health Organization. Tobacco. May 2022 [internet publication].[Full Text]
8. US Department of Health and Human Services. The health consequences of smoking - 50 years of progress. A report of the Surgeon General. Jan 2014 [internet publication].[Full Text]
9. GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022 Aug 20;400(10352):563-91.[Abstract][Full Text]
10. Hackshaw A, Morris JK, Boniface S, et al. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ. 2018 Jan 24;360:j5855.[Abstract][Full Text]
11. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004 Jun 26;328(7455):1519.[Abstract][Full Text]
12. Messer K, Pierce J, Zhu S-H, et al. The California Tobacco Control Program's effect on adult smokers: (1) Smoking cessation. Tob Control. 2007 Apr;16(2):85-90.[Abstract][Full Text]
13. Hummel K, Nagelhout GE, Fong GT, et al. Quitting activity and use of cessation assistance reported by smokers in eight European countries: findings from the EUREST-PLUS ITC Europe Surveys. Tob Induc Dis. 2018;16(2 suppl):A6.[Abstract][Full Text]
14. Beard E, Jackson SE, West R, et al. Trends in attempts to quit smoking in England since 2007: a time series analysis of a range of population-level influences. Nicotine Tob Res. 2020 Aug 24;22(9):1476-83.[Abstract]
15. Gravely S, Cummings KM, Hammond D, et al. Self-reported quit aids and assistance used by smokers at their most recent quit attempt: findings from the 2020 international tobacco control four country smoking and vaping survey. Nicotine Tob Res. 2021 Aug 29;23(10):1699-707.[Abstract][Full Text]
16. Lange S, Probst C, Rehm J, et al. National, regional, and global prevalence of smoking during pregnancy in the general population: a systematic review and meta-analysis. Lancet Glob Health. 2018 Jul;6(7):e769-76.[Abstract][Full Text]
17. Drake P, Driscoll AK, Mathews TJ. Cigarette smoking during pregnancy: United States, 2016. NCHS Data Brief. 2018 Feb;(305):1-8.[Abstract][Full Text]
18. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1923-94.[Abstract][Full Text]
19. US Department of Health and Human Services. Let's make the next generation tobacco-free: your guide to the 50th anniversary surgeon general's report on smoking and health. Jul 2015 [internet publication].[Full Text]
20. Mays D, Gilman SE, Rende R, et al. Parental smoking exposure and adolescent smoking trajectories. Pediatrics. 2014 Jun;133(6):983-91.[Abstract]
21. Prom-Wormley EC, Clifford JS, Cooke ME, et al. The genetic and environmental influences contributing to the association between electronic and conventional cigarette initiation. Nicotine Tob Res. 2021 May 4;23(5):856-60.[Abstract]
22. Hartz SM, Pato CN, Medeiros H, et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry. 2014 Mar;71(3):248-54.[Abstract][Full Text]
23. Bandiera FC, Anteneh B, Le T, et al. Tobacco-related mortality among persons with mental health and substance abuse problems. PLoS One. 2015;10(3):e0120581.[Abstract][Full Text]
24. Ding JB, Hu K. Cigarette smoking and schizophrenia: etiology, clinical, pharmacological, and treatment implications. Schizophr Res Treatment. 2021;2021:7698030.[Abstract][Full Text]
25. Pacek LR, Cioe PA. Tobacco use, use disorders, and smoking cessation interventions in persons living with HIV. Curr HIV/AIDS Rep. 2015 Dec;12(4):413-20.[Abstract]
26. Gentzke AS, Wang TW, Cornelius M, et al. Tobacco product use and associated factors among middle and high school students - National Youth Tobacco Survey, United States, 2021. MMWR Surveill Summ. 2022 Mar 11;71(5):1-29.[Abstract][Full Text]
27. Donaldson SI, Dormanesh A, Escobedo P, et al. The impact of e-cigarette product place in music videos on susceptibility to use e-cigarettes among young adults: an experimental investigation. Addict Behav. 2022 Jul;130:107307.[Abstract]
28. Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2009;49:57-71.[Abstract]
29. Lindson N, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2019 Apr 18;4(4):CD013308.[Abstract][Full Text]
30. Loud EE, Duong HT, Henderson KC, et al. Addicted to smoking or addicted to nicotine? A focus group study on perceptions of nicotine and addiction among US adult current smokers, former smokers, non-smokers and dual users of cigarettes and e-cigarettes. Addiction. 2022 Feb;117(2):472-81.[Abstract]
31. Wold LE, Tarran R, Crotty Alexander LE, et al. Cardiopulmonary consequences of vaping in adolescents: a scientific statement from the American Heart Association. Circ Res. 2022 Jul 22;131(3):e70-82.[Abstract][Full Text]
32. European Lung Foundation; European Respiratory Society. E-cigarettes, heat-not-burn and smokeless tobacco products. Breathe (Sheff). 2020 Mar;16(1):161ELF.[Abstract][Full Text]
33. Perrine CG, Pickens CM, Boehmer TK, et al. Characteristics of a multistate outbreak of lung injury associated with e-cigarette use, or vaping - United States, 2019. MMWR Morb Mortal Wkly Rep. 2019 Oct 4;68(39):860-4.[Abstract][Full Text]
34. Rebuli ME, Rose JJ, Noël A, et al. The e-cigarette or vaping product use-associated lung injury epidemic: pathogenesis, management, and future directions: an official American Thoracic Society workshop report. Ann Am Thorac Soc. 2023 Jan;20(1):1-17.[Abstract][Full Text]
35. Qasim H, Alarabi AB, Alzoubi KH, et al. The effects of hookah/waterpipe smoking on general health and the cardiovascular system. Environ Health Prev Med. 2019 Sep 14;24(1):58.[Abstract][Full Text]
36. Gravely S, Giovino GA, Craig L, et al. Implementation of key demand-reduction measures of the WHO Framework Convention on Tobacco Control and change in smoking prevalence in 126 countries: an association study. Lancet Public Health. 2017 Apr;2(4):e166-74.[Abstract][Full Text]
37. Levy DT, Tam J, Kuo C, et al. The impact of implementing tobacco control policies: the 2017 tobacco control policy scorecard. J Public Health Manag Pract. 2018 Sep/Oct;24(5):448-57.[Abstract][Full Text]
38. National Institute on Drug Abuse. How can we prevent tobacco use? May 2022 [internet publication].[Full Text]
39. Adachi-Mejia AM, Carlos HA, Berke EM, et al. A comparison of individual versus community influences on youth smoking behaviours: a cross-sectional observational study. BMJ Open. 2012;2(5):e000767.[Abstract][Full Text]
40. Warner KE. Tobacco control policies and their impacts. Past, present, and future. Ann Am Thorac Soc. 2014 Feb;11(2):227-30.[Abstract][Full Text]
41. Farrelly MC, Davis KC, Haviland ML, et al. Evidence of a dose-response relationship between "truth" antismoking ads and youth smoking prevalence. Am J Public Health. 2005 Mar;95(3):425-31.[Abstract][Full Text]
42. Centers for Disease Control and Prevention. Tips from former smokers. Sep 2022 [internet publication].[Full Text]
43. Murphy-Hoefer R, Davis KC, King BA, et al. Association between the tips from former smokers campaign and smoking cessation among adults, United States, 2012-2018. Prev Chronic Dis. 2020 Aug 27;17:E97.[Abstract][Full Text]
44. Stead LF, Buitrago D, Preciado N, et al. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2013;(5):CD000165.[Abstract][Full Text]
45. US Preventive Services Task Force; Krist AH, Davidson KW, Mangione CM, et al. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. JAMA. 2021 Jan 19;325(3):265-79.[Abstract][Full Text]
46. National Institute for Health and Care Excellence. Tobacco: preventing uptake, promoting quitting and treating dependence. Jan 2023 [internet publication].[Full Text]
47. Swartz S, Hays J. Office-based intervention for tobacco dependence. Med Clin North Am. 2004 Nov;88(6):1623-41;xii-iii.[Abstract]
48. Polubriaginof F, Salmasian H, Albert DA, et al. Challenges with collecting smoking status in electronic health records. AMIA Annu Symp Proc. 2017;2017:1392-400.[Abstract][Full Text]
49. Rigotti NA, Kruse GR, Livingstone-Banks J, et al. Treatment of tobacco smoking: a review. JAMA. 2022 Feb 8;327(6):566-77.[Abstract]
50. Aveyard P, Massey L, Parsons A, et al. The effect of Transtheoretical Model based interventions on smoking cessation. Soc Sci Med. 2009 Feb;68(3):397-403.[Abstract]
51. Kim S. Overview of cotinine cutoff values for smoking status classification. Int J Environ Res Public Health. 2016 Dec 14;13(12):1236.[Abstract][Full Text]
52. Duchman KR, Gao Y, Pugely AJ, et al. The effect of smoking on short-term complications following total hip and knee arthroplasty. J Bone Joint Surg Am. 2015 Jul 1;97(13):1049-58.[Abstract]
53. Hart A, Rainer WG, Taunton MJ, et al. Cotinine testing improves smoking cessation before total joint arthroplasty. J Arthroplasty. 2019 Jul;34(7s):S148-51.[Abstract]
54. American Society of Addiction Medicine. Integrating tobacco use disorder interventions in addiction treatment. 2022 [internet publication].[Full Text]
55. Fluharty M, Taylor AE, Grabski M, et al. The association of cigarette smoking with depression and anxiety: a systematic review. Nicotine Tob Res. 2017 Jan;19(1):3-13.[Abstract][Full Text]
56. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013;(2):CD007253.[Abstract][Full Text]
57. Siskind DJ, Wu BT, Wong TT, et al. Pharmacological interventions for smoking cessation among people with schizophrenia spectrum disorders: a systematic review, meta-analysis, and network meta-analysis. Lancet Psychiatry. 2020 Sep;7(9):762-74.[Abstract]
58. Barua RS, Rigotti NA, Benowitz NL, et al. 2018 ACC expert consensus decision pathway on tobacco cessation treatment: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2018 Dec 5;72(25):3332-65.[Abstract][Full Text]
59. Benowitz NL, Pipe A, West R, et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Intern Med. 2018 May 1;178(5):622-31.[Abstract][Full Text]
60. Soulakova JN, Hartman AM, Liu B, et al. Reliability of adult self-reported smoking history: data from the tobacco use supplement to the current population survey 2002-2003 cohort. Nicotine Tob Res. 2012 Aug;14(8):952-60.[Abstract]
61. Benowitz NL, Bernert JT, Foulds J, et al. Biochemical verification of tbacco use and abstinence: 2019 update. Nicotine Tob Res. 2020 Jun 12;22(7):1086-97.[Abstract][Full Text]
62. Lager PS, Attema-de Jonge ME, Gorzeman MP, et al. Clinical value of drugs of abuse point of care testing in an emergency department setting. Toxicol Rep. 2018;5:12-17.[Abstract][Full Text]
63. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
64. Aveyard P, West R. Managing smoking cessation. BMJ. 2007 Jul 7;335(7609):37-41.[Abstract][Full Text]
65. Jenssen BP, Walley SC, Boykan R, et al. Protecting children and adolescents from tobacco and nicotine. Pediatrics. 2023 May 1;151(5):e2023061805.[Full Text]
66. Linder JA, Rigotti NA, Schneider LI, et al. An electronic health record-based intervention to improve tobacco treatment in primary care: a cluster-randomized controlled trial. Arch Intern Med. 2009;169:781-787. [Abstract]
67. Aveyard P, Begh R, Parsons A, et al. Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. Addiction. 2012 Jun;107(6):1066-73.[Abstract]
68. Borland R, Balmford J, Bishop N, et al. In-practice management versus quitline referral for enhancing smoking cessation in general practice: a cluster randomized trial. Fam Pract. 2008 Oct;25(5):382-9.[Abstract][Full Text]
69. American Academy of Family Physicians. Ask and act: a tobacco cessation program. 2010 [internet publication].[Full Text]
70. Clair C, Mueller Y, Livingstone-Banks J, et al. Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev. 2019 Mar 26;3(3):CD004705.[Abstract][Full Text]
71. Chamberlain C, O'Mara-Eves A, Porter J, et al. Psychosocial interventions for supporting women to stop smoking in pregnancy. Cochrane Database Syst Rev. 2017;(2):CD001055.[Abstract][Full Text]
72. Claire R, Chamberlain C, Davey MA, et al. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2020 Mar 4;3(3):CD010078.[Abstract][Full Text]
73. Fanshawe TR, Halliwell W, Lindson N, et al. Tobacco cessation interventions for young people. Cochrane Database Syst Rev. 2017 Nov 17;(11):CD003289.[Abstract][Full Text]
74. Stead LF, Carroll AJ, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev. 2017;(3):CD001007.[Abstract][Full Text]
75. Chen YF, Madan J, Welton N, et al. Effectiveness and cost-effectiveness of computer and other electronic aids for smoking cessation: a systematic review and network meta-analysis. Health Technol Assess. 2012;16(38):1-205, iii-v.[Abstract][Full Text]
76. Taylor GMJ, Dalili MN, Semwal M, et al. Internet-based interventions for smoking cessation. Cochrane Database Syst Rev. 2017;(4):CD007078.[Abstract][Full Text]
77. Scott-Sheldon LA, Lantini R, Jennings EG, et al. Text messaging-based interventions for smoking cessation: a systematic review and meta-analysis. JMIR Mhealth Uhealth. 2016 May 20;4(2):e49.[Abstract][Full Text]
78. Whittaker R, McRobbie H, Bullen C, et al. Mobile phone text messaging and app-based interventions for smoking cessation. Cochrane Database Syst Rev. 2019 Oct 22;10(10):CD006611.[Abstract][Full Text]
79. Stead LF, Koilpillai P, Fanshawe TR, et al. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2016 Mar 24;3:CD008286.[Abstract][Full Text]
80. Kendzor DE, Businelle MS, Poonawalla IB, et al. Financial incentives for abstinence among socioeconomically disadvantaged individuals in smoking cessation treatment. Am J Public Health. 2015 Jun;105(6):1198-205.[Abstract][Full Text]
81. Notley C, Gentry S, Livingstone-Banks J, et al. Incentives for smoking cessation. Cochrane Database Syst Rev. 2019 Jul 17;7(7):CD004307.[Abstract][Full Text]
82. Halpern SD, French B, Small DS, et al. Randomized trial of four financial-incentive programs for smoking cessation. N Engl J Med. 2015 May 28;372(22):2108-17.[Abstract][Full Text]
83. Hartmann-Boyce J, Livingstone-Banks J, Ordóñez-Mena JM, et al. Behavioural interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2021 Jan 4;1:CD013229.[Abstract][Full Text]
84. Centers for Disease Control and Prevention. Tips from former smokers campaign: build your quit plan. Aug 2022 [internet publication]. [Full Text]
85. Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018 May 31;(5):CD000146.[Abstract][Full Text]
86. Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009 Nov;66(11):1253-62. [Abstract][Full Text]
87. Office for Health Improvement and Disparities. Nicotine vaping in England: an evidence update including health risks and perceptions, 2022. Sep 2022 [internet publication].[Full Text]
88. Hartmann-Boyce J, Lindson N, Butler AR, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD010216.[Abstract]
89. US Food and Drug Administration. E-cigarettes, vapes, and other electronic nicotine delivery systems (ENDS). Jun 2022 [internet publication].[Full Text]
90. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Review of the Health Effects of Electronic Nicotine Delivery Systems; Eaton DL, Kwan LY, Stratton K. Public health consequences of e-cigarettes. Washington, DC: National Academies Press; 2018.[Abstract][Full Text]
91. Rose JJ, Krishnan-Sarin S, Exil VJ, et al. Cardiopulmonary impact of electronic cigarettes and vaping products: a scientific statement from the American Heart Association. Circulation. 2023 Aug 22;148(8):703-28.[Abstract][Full Text]
92. Cobb NK, Byron MJ, Abrams DB, et al. Novel nicotine delivery systems and public health: the rise of the "e-cigarette". Am J Public Health. 2010 Dec;100(12):2340-2.[Abstract][Full Text]
93. Public Health England (UK). Evidence review of e-cigarettes and heated tobacco products 2018: executive summary. Mar 2018 [internet publication].[Full Text]
94. Stephens WE. Comparing the cancer potencies of emissions from vapourised nicotine products including e-cigarettes with those of tobacco smoke. Tob Control. 4 Aug 2017 [Epub ahead of print].[Abstract][Full Text]
95. Herbst RS, Hatsukami D, Acton D, et al. Electronic Nicotine Delivery Systems: an updated policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. J Clin Oncol. 2022 Dec 10;40(35):4144-55.[Abstract][Full Text]
96. Cahill K, Lindson-Hawley N, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016;(5):CD006103.[Abstract][Full Text]
97. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507-20.[Abstract]
98. Beard E, Jackson SE, Anthenelli RM, et al. Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors. Addiction. 2021;116(10):2816-24.[Abstract][Full Text]
99. Hughes J, Goldstein M, Hurt R, et al. Recent advances in the pharmacotherapy of smoking. JAMA. 1999 Jan 6;281(1):72-6.[Abstract]
100. Bader P, McDonald P, Selby P. An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts. Tob Control. 2009 Feb;18(1):34-42. [Abstract][Full Text]
101. Thomas KH, Dalili MN, López-López JA, et al. Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta-analysis of randomized controlled trials. Addiction. 2022 Apr;117(4):861-76.[Abstract][Full Text]
102. Windle SB, Filion KB, Mancini JG, et al. Combination therapies for smoking cessation: a hierarchical Bayesian meta-analysis. Am J Prev Med. 2016 Dec;51(6):1060-71.[Abstract]
103. Baker TB, Piper ME, Smith SS, et al. Effects of combined varenicline with nicotine patch and of extended treatment duration on smoking cessation: a randomized clinical trial. JAMA. 2021 Oct 19;326(15):1485-93.[Abstract][Full Text]
104. Shiffman S, Ferguson SG. Nicotine patch therapy prior to quitting smoking: a meta-analysis. Addiction. 2008 Apr;103(4):557-63. [Abstract]
105. Shiffman S, Ferguson SG, Strahs KR. Quitting by gradual smoking reduction using nicotine gum: a randomized controlled trial. Am J Prev Med. 2009 Feb;36(2):96-104;e1. [Abstract]
106. Moore D, Aveyard P, Connock M, et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ. 2009 Apr 2;338:b1024. [Abstract][Full Text]
107. Ebbert JO, Hughes JR, West RJ, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA. 2015 Feb 17;313(7):687-94. [Abstract][Full Text]
108. Lindson N, Klemperer E, Hong B, et al. Smoking reduction interventions for smoking cessation. Cochrane Database Syst Rev. 2019 Sep 30;9(9):CD013183.[Abstract][Full Text]
109. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2017;(3):CD001292.[Abstract][Full Text]
110. Dietz PM, England LJ, Shapiro-Mendoza CK, et al. Infant morbidity and mortality attributable to prenatal smoking in the U.S. Am J Prev Med. 2010 Jul;39(1):45-52.[Abstract][Full Text]
111. American College of Obstetricians and Gynecologists. Tobacco and nicotine cessation during pregnancy: committee opinion, number 807. May 2020 [internet publication].[Full Text]
112. Hickson C, Lewis S, Campbell KA, et al. Comparison of nicotine exposure during pregnancy when smoking and abstinent with nicotine replacement therapy: systematic review and meta-analysis. Addiction. 2019 Mar;114(3):406-24.[Abstract][Full Text]
113. Thomas RE, Baker PR, Thomas BC, et al. Family-based programmes for preventing smoking by children and adolescents. Cochrane Database Syst Rev. 2015;(2):CD004493.[Abstract][Full Text]
114. US Preventive Services Task Force; Owens DK, Davidson KW, Krist AH, et al. Primary care interventions for prevention and cessation of tobacco use in children and adolescents: US Preventive Services Task Force recommendation statement. JAMA. 2020 Apr 28;323(16):1590-8.[Abstract][Full Text]
115. Squeglia LM, Fadus MC, McClure EA, et al. Pharmacological treatment of youth substance use disorders. J Child Adolesc Psychopharmacol. 2019 Aug;29(7):559-72.[Abstract]
116. Bailey SR, Hagen SA, Jeffery CJ, et al. A randomized clinical trial of the efficacy of extended smoking cessation treatment for adolescent smokers. Nicotine Tob Res. 2013 Oct;15(10):1655-62.[Abstract][Full Text]
117. Myung SK, Park JY. Efficacy of pharmacotherapy for smoking cessation in adolescent smokers: a meta-analysis of randomized controlled trials. Nicotine Tob Res. 2019 Oct 26;21(11):1473-9.[Abstract]
118. Gray KM, Baker NL, McClure EA, et al. Efficacy and safety of varenicline for adolescent smoking cessation: a randomized clinical trial. JAMA Pediatr. 2019 Dec 1;173(12):1146-53.[Abstract][Full Text]
119. Fiore MC, Goplerud E, Schroeder SA. The Joint Commission's new tobacco-cessation measures--will hospitals do the right thing? N Engl J Med. 2012 Mar 29;366(13):1172-4.[Abstract][Full Text]
120. Rigotti NA, Clair C, Munafò MR, et al. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2012 May 16;5(5):CD001837.[Abstract]
121. Stefan MS, Pack Q, Shieh MS, et al. The association of nicotine replacement therapy with outcomes among smokers hospitalized for a major surgical procedure. Chest. 2020 May;157(5):1354-61.[Abstract]
122. Grønkjær M, Eliasen M, Skov-Ettrup LS, et al. Preoperative smoking status and postoperative complications: a systematic review and meta-analysis. Ann Surg. 2014 Jan;259(1):52-71.[Abstract]
123. Theadom A, Cropley M. Effects of preoperative smoking cessation on the incidence and risk of intraoperative and postoperative complications in adult smokers: a systematic review. Tob Control. 2006 Oct;15(5):352-8.[Abstract]
124. Wong J, Abrishami A, Riazi S, et al. A perioperative smoking cessation intervention with varenicline, counseling, and fax referral to a telephone quitline versus a brief intervention: a randomized controlled trial. Anesth Analg. 2017 Aug;125(2):571-9.[Abstract][Full Text]
125. Warner DO. Perioperative abstinence from cigarettes: physiologic and clinical consequences. Anesthesiology. 2006 Feb;104(2):356-67.[Abstract][Full Text]
126. Bernstein SL, D'Onofrio G, Rosner J, et al. Successful tobacco dependence treatment in low-income emergency department patients: a randomized trial. Ann Emerg Med. 2015 Aug;66(2):140-7. [Abstract][Full Text]
127. Hughes J. Depression during tobacco abstinence. Nicotine Tob Res. 2007 Apr;9(4):443-6.[Abstract]
128. Apollonio D, Philipps R, Bero L. Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. Cochrane Database Syst Rev. 2016 Nov 23;11(11):CD010274.[Abstract][Full Text]
129. Guo K, Li J, Li J, et al. The effects of pharmacological interventions on smoking cessation in people with alcohol dependence: a systematic review and meta-analysis of nine randomized controlled trials. Int J Clin Pract. 2021 Nov;75(11):e14594.[Abstract]
130. van Amsterdam J, van den Brink W. Smoking as an outcome moderator in the treatment of alcohol use disorders. Alcohol Alcohol. 2022 Nov 11;57(6):664-63.[Abstract][Full Text]
131. Ebbert JO, Elrashidi MY, Stead LF. Interventions for smokeless tobacco use cessation. Cochrane Database Syst Rev. 2015 Oct 26;2015(10):CD004306.[Abstract][Full Text]
132. Nethan ST, Sinha DN, Chandan K, et al. Smokeless tobacco cessation interventions: a systematic review. Indian J Med Res. 2018 Oct;148(4):396-410.[Abstract][Full Text]
133. Nethan ST, Sinha DN, Sharma S, et al. Behavioral interventions for smokeless tobacco cessation. Nicotine Tob Res. 2020 Apr 17;22(4):588-93.[Abstract]
134. Maziak W, Jawad M, Jawad S, et al. Interventions for waterpipe smoking cessation. Cochrane Database Syst Rev. 2015;(7):CD005549.[Abstract]
135. Howes S, Hartmann-Boyce J, Livingstone-Banks J, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2020 Apr 22;4(4):CD000031.[Abstract][Full Text]
136. US Food and Drug Administration (FDA). FDA notice: varenicline (marketed as Chantix) and bupropion (marketed as Zyban, Wellbutrin, and generics) - Black Box warning. Jul 2009 [internet publication].
137. Jones SK, Wolf BJ, Froeliger B, et al. Nicotine metabolism predicted by CYP2A6 genotypes in relation to smoking cessation: a systematic review. Nicotine Tob Res. 2022 Mar 26;24(5):633-42.[Abstract][Full Text]
138. Jones SK, Wolf BJ, Froeliger B, et al. A systematic review of genetic variation within nicotinic acetylcholine receptor genes and cigarette smoking cessation. Drug Alcohol Depend. 2022 Oct 1;239:109596.[Abstract]
139. Chen LS, Horton A, Bierut L. Pathways to precision medicine in smoking cessation treatments. Neurosci Lett. 2018 Mar 16;669:83-92.[Abstract]
140. Cornuz J, Zwahlen S, Jungi WF, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One. 2008 Jun 25;3(6):e2547.[Abstract][Full Text]
141. Hartmann-Boyce J, Cahill K, Hatsukami D, et al. Nicotine vaccines for smoking cessation. Cochrane Database Syst Rev. 2012;(8):CD007072.[Abstract]
142. Celik M, Fuehrlein B. A review of immunotherapeutic approaches for substance use disorders: current status and future prospects. Immunotargets Ther. 2022;11:55-66.[Abstract][Full Text]
143. Saravia R, Ten-Blanco M, Pereda-Pérez I, et al. New insights in the involvement of the endocannabinoid system and natural cannabinoids in nicotine dependence. Int J Mol Sci. 2021 Dec 10;22(24):13316.[Abstract][Full Text]
144. Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane Database Syst Rev. 2011;(3):CD005353.[Abstract]
145. Galaj E, Xi ZX. Potential of cannabinoid receptor ligands as treatment for substance use disorders. CNS Drugs. 2019 Oct;33(10):1001-30.[Abstract]
146. Dinur-Klein L, Dannon P, Hadar A, et al. Smoking cessation induced by deep repetitive transcranial magnetic stimulation of the prefrontal and insular cortices: a prospective, randomized controlled trial. Biol Psychiatry. 2014 Nov 1;76(9):742-9.[Abstract][Full Text]
147. Zangen A, Moshe H, Martinez D, et al. Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial. World Psychiatry. 2021 Oct;20(3):397-404.[Abstract][Full Text]
148. Barnes J, McRobbie H, Dong CY, et al. Hypnotherapy for smoking cessation. Cochrane Database Syst Rev. 2019 Jun 14;6(6):CD001008.[Abstract][Full Text]
149. Wang JH, van Haselen R, Wang M, et al. Acupuncture for smoking cessation: a systematic review and meta-analysis of 24 randomized controlled trials. Tob Induc Dis. 2019;17:48.[Abstract][Full Text]
150. Bock BC, Dunsiger SI, Rosen RK, et al. Yoga as a complementary therapy for smoking cessation: results from BreathEasy, a randomized clinical trial. Nicotine Tob Res. 2019 Oct 26;21(11):1517-23.[Abstract]
151. Jackson S, Brown J, Norris E, et al. Mindfulness for smoking cessation. Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD013696.[Abstract][Full Text]
152. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: smoking cessation [internet publication].[Full Text]
153. Centers for Disease Control and Prevention. Smoking and tobacco use: clinical cessation tools. Dec 2021 [internet publication].[Full Text]
154. Leone FT, Zhang Y, Evers-Casey S, et al. Initiating pharmacologic treatment in tobacco-dependent adults. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020 Jul 15;202(2):e5-31.[Abstract][Full Text]
155. Canadian Task Force on Preventive Health Care. Tobacco smoking in children and adolescents. 2017 [internet publication].[Full Text]
156. Registered Nurses' Association of Ontario. Integrating tobacco interventions into daily practice. Jun 2017 [internet publication].[Full Text]
157. Hughes J, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004 Jan;99(1):29-38.[Abstract]
158. Livingstone-Banks J, Norris E, Hartmann-Boyce J, et al. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev. 2019 Oct 28;2019(10):CD003999.[Abstract][Full Text]
159. Shahab L, McEwen A. Online support for smoking cessation: a systematic review of the literature. Addiction. 2009 Nov;104(11):1792-804. [Abstract][Full Text]
160. Schnoll RA, Patterson F, Wileyto EP, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med. 2010 Feb 2;152(3):144-51. [Abstract][Full Text]
161. Cooney JL, Cooney NL, Pilkey DT, et al. Effects of nicotine deprivation on urges to drink and smoke in alcoholic smokers. Addiction. 2003 Jul;98(7):913-21.[Abstract]
162. Colby SM, Rohsenow DJ, Monti PM, et al. Effects of tobacco deprivation on alcohol cue reactivity and drinking among young adults. Addict Behav. 2004 Jul;29(5):879-92.[Abstract]
163. Aubin HJ, Farley A, Lycett D, et al. Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ. 2012 Jul 10;345:e4439. [Abstract][Full Text]
164. Kim K, Park SM, Lee K. Weight gain after smoking cessation does not modify its protective effect on myocardial infarction and stroke: evidence from a cohort study of men. Eur Heart J. 2018 May 1;39(17):1523-31.[Abstract][Full Text]
165. Hartmann-Boyce J, Theodoulou A, Farley A, et al. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2021 Oct 6;10(10):CD006219.[Abstract]
166. Yang M, Bhowmik D, Wang X, et al. Does combination pharmacological intervention for smoking cessation prevent post-cessation weight gain? A systemic review. Addict Behav. 2013 Mar;38(3):1865-75.[Abstract]
167. Schaffer SD, Yoon S, Zadezensky I. A review of smoking cessation: potentially risky effects on prescribed medications. J Clin Nurs. 2009 Jun;18(11):1533-40.[Abstract]
168. Wu AD, Lindson N, Hartmann-Boyce J, et al. Smoking cessation for secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2022 Aug 8;8(8):CD014936.[Abstract]
169. van den Brand FA, Nagelhout GE, Reda AA, et al. Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database Syst Rev. 2017;(9):CD004305.[Abstract][Full Text]
170. Mills AL, Messer K, Gilpin EA, et al. The effect of smoke-free homes on adult smoking behavior: a review. Nicotine Tob Res. 2009 Oct;11(10):1131-41. [Abstract]
171. Guilamo-Ramos V, Jaccard J, Dittus P, et al. The Linking Lives health education program: a randomized clinical trial of a parent-based tobacco use prevention program for African American and Latino youths. Am J Public Health. 2010 Sep;100(9):1641-7.[Abstract][Full Text]
